Skip to contentV
Viridian Therapeutics, Inc.
V
VRDNViridian Therapeutics, Inc. Q2 2020 · 10-Q
Revenue$168.00K$168.00K−93.3% vs Q2 2019 Net Income-$6.44M-$6.44MN/M vs Q2 2019 EPS Diluted-$1.82-$1.82N/M vs Q2 2019 Operating Income-$6,374,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Viridian Therapeutics, Inc. · CIK 1590750 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$6,789,000N/M Margins · derivedOperating margin-3794.0%−3438.4 pt vs Q2 2019
Net margin-3830.4%−3476.5 pt vs Q2 2019
ended Jun 30, 2020 · filed Aug 5, 2020 · 36 d after period end